Seeking Alpha


Send Message
View as an RSS Feed
Latest  |  Highest rated
  • Sangamo BioSciences (SGMO -4.5%) takes a bit of a hit this morning, despite the presentation of new data demonstrating the successful application of its In Vivo Protein Replacement Platform in a mouse model. The company, in partnership with Shire (SHPG +1.8%), is developing ZFP Therapeutics for both hemophilia A and B using this approach. The data was presented late last week at the 16th Annual Meeting of the American Society of Gene and Cell Therapy in Salt Lake City. [View news story]
    SGMO failed to turn sandstone into gold or demonstrate 100%
    HIV eradication from blood and reservoirs.
    Hot and scared money left.
    I counsel patience. With all that SGMO has learned to date,
    The next trials will show even better results against
    more targeted heterozygous groups of patients.
    May 20, 2013. 01:36 PM | Likes Like |Link to Comment
1 Comment